SEARCH

SEARCH BY CITATION

References

  • 1
    Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A et al. The spectrum of bone disease in end-stage renal failure – an evolving disorder. Kid Int 1993; 43: 436 42.
  • 2
    Coburn J. Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis. Kid Int 1993, Supplement 40: S92 S100.
  • 3
    Slatopolsky E & Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kid Dis 1994; 23 (2): 229 36.
  • 4
    Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG et al. ‘High-dose’ calcitriol for control of renal osteodystrophy in children on CAPD. Kid Int 1987; 32: 89 95.
  • 5
    Carozzi S, Nasini MG, Schelotto C, Caviglia PM, Santoni O, Pietrucci A. . Low calcium peritoneal dialysis solution. Effects on calcium metabolism and bone disease in CAPD patients ASAIO J 1992; 38: M593 M595.
  • 6
    Martin KJ, Ballal S, Domoto DT, Blalock S, Weindel M. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations. Am J Kid Dis 1992; 19 (6): 540 55.
  • 7
    Juergensen PH, Finkelstein FO, Cooper K, Santacroce S, Kliger AS. Hyperparathyroidism in CAPD patients. Therapy with pulse oral calcitriol Adv Perit Dial 1993; 9: 257 9.
  • 8
    Wadhwa NK, Suh H, Howell N, Cabralda T, Sokunbi D, Solomon M. Pulse. Intravenous calcitriol therapy of secondary hyperparathyroidsm in peritoneal dialysis patients Adv Perit Dial 1993; 9: 260 63.
  • 9
    Rolla D, Paoletti E, Marsano L, Mulas D, Peloso G, Cannella G. Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Perit Dial Int 1993; 13: 118 21.
  • 10
    Delmez JA, Dougan S, Gearing BK, Rothstein M, Windus DW, Rapp N et al. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kid Int 1987; 31: 795 9.
  • 11
    Arora N, Sandroni S, Moles K. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol. Adv Perit Dial 1992; 8: 62 4.
  • 12
    Fournier A, Morinière Ph Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H et al. 1-Alpha-hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Nephron 1995; 71: 254 83.
  • 13
    Brancaccio D & Gallieni M. Recent advances in intravenous calcitriol treatment. Curr Opin Nephrol Hyp 1994; 3: 411 6.
  • 14
    Fischer ER & Harris DCH. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993; 40 (4): 216 20.
  • 15
    Quarles D, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kid Int 1994; 45: 1710 21.
  • 16
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K. Long-term effects of intravenous 1α (OH) D3, CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. Nephron 1996; 74: 89 103.
  • 17
    Twardowski Z, Nolph K, Khanna R, Prowant B, Ryan L, Moore H et al. Peritoneal equilibration test. Perit Dial Bull 1987; 3: 138 47.
  • 18
    Daugaard H, Egfjord M, Olgaard K. Metabolism of intact parathyroid hormone in isolated perfused rat liver and kidney. Am J Physiol 1988; 254: E740 48.
  • 19
    Reinhardt TA, Horst RL, Orf JW, Hollis BW. A microassay for 1,25dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab 1984; 58: 91 8.
  • Altman DG.
    Practical Statistics for Medical Research London: Chapman and Hall, 1991.
  • 21
    Yasuda T, Ozawa S, Shiba C, Maeba T, Kanazawa T, Sugiyama M et al. D-lactate metabolism in patients with chronic renal failure undergoing CAPD. Nephron 1993; 63: 416 22.
  • 22
    Hutchinson AJ, Freemont AJ, Boulton HF, Gokal R. Low-calcium dialysis fluid an oral calciumcarbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcemia. Nephrol Dial Transplant 1992; 7: 1219 25.
  • 23
    Delmez JA. Removal of phosphorus by peritoneal dialysis. Perit Dial Int 1993; 13 (Suppl. 2): S461 S463.
  • 24
    Brown CB, Hamdy NAT, Boletis J, Boyle G, Beneton MNC, Charlesworth D et al. . Osteodystrophy in continous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 (Suppl. 2): S454 S460.
  • 25
    Pagliari B, Baretta A, Cristofaro V, Samà F, Cantaluppi A, Martis L et al. Short-term effects of low-calcium dialysis solutions on calcium mass transfer, ionized calcium, and parathyroid hormone in CAPD patients. Perit Dial Int 1991; 11: 326 9.
  • 26
    Weinreich T, Colombi A, Echterhoff HH, Mielke G, Nebel M, Ziegelmayer C et al. Transperitoneal calcium mass transfer using dialysate with a low calcium concentration (1.0 mm) Perit Dial Int 1993; 13 (Suppl. 2): S467 S470.
  • 27
    Piraino B, Bernardini J, Holley J, Johnston JR, Perlmutter JA, Martis L. Calcium mass transfer in peritoneal dialysis patients using 2.5 Meq L−1 Calcium Dialysate Clin Nephrol 1992; 37 (1): 48 51.
  • 28
    Hutchison AJ, Merchant M, Boulton HF, Hinchcliffe R, Gokal R. Calcium and Magensium Mass Transfer in Peritoneal Dialysis Patients using 1.25 mmol L−1 Calcium, 0.25 mmol L−1 magnesium dialysis fluid. Perit Dial Int 1993; 13: 219 23.
  • 29
    Meema H, Orepoulos D, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kid Int 1987; 32: 388 94.
  • 30
    Gonella M, Ballanti P, Della Rocca C. Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients. Miner Electrolyte Metab 1988; 14: 240.